OClawVPS.com
ASLAN Pharma
Edit

ASLAN Pharma

http://www.aslanpharma.com/
Last activity: 05.08.2024
Active
Categories: BioTechDevelopmentDrugInformationMedtech
ASLAN Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients.

ASLAN is currently evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease. ASLAN has a team in Menlo Park, California, and in Singapore.

For additional information please visit www.aslanpharma.com.
Followers
257
Mentions
27
Location: Singapore
Employees: 51-200
Total raised: $150M
Founded date: 2010
Twitter
LinkedIn
Email

Investors 2

Funding Rounds 5

DateSeriesAmountInvestors
12.03.2024-$5M-
13.07.2021-$45M-
04.07.2016Pre-IPO$23M-
07.01.2016Series C$43M-
08.12.2015Series C$34M-

Mentions in press and media 27

DateTitleDescription
05.08.2024QBIOTICS WELCOMES STEPHEN DOYLE AS CHIEF EXECUTIVE OFFICERStephen Doyle has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and Boehringer Ingelheim. He was most recently Chief Business Officer at Aslan Ph...
05.08.2024QBIOTICS WELCOMES STEPHEN DOYLE AS CHIEF EXECUTIVE OFFICERStephen Doyle has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and Boehringer Ingelheim. He was most recently Chief Business Officer at Aslan Ph...
13.03.2024ASLAN Pharmaceuticals Secures $5 Million in Direct OfferingASLAN Pharmaceuticals, a biopharmaceutical company on a mission to revolutionize patient care, has clinched a $5 million deal through a direct offering. The company has struck a definitive agreement to sell 5,000,000 of its American Deposit...
12.03.2024ASLAN Pharmaceuticals Announces $5 Million Registered Direct OfferingSAN MATEO, Calif. and SINGAPORE, March 12, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patient...
12.03.2024ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering-
06.03.2024ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors-
28.10.2022ASLAN Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateCompany maintains healthy operating position with US$68.9 million in cash, cash equivalents and short-term investments as of September 30, 2022; expected runway through late 2023 New TREK-DX clinical program studying eblasakimab’s potential...
21.01.2022Accompanying slides, A4 KOL Series: Episode 2, Dr April ArmstrongASLAN A4 Series: Aspects of Atopic Dermatitis and ASLAN004 with Dr April Armstrong 20 January 2022 NASDAQ: ASLN 1 Aspects of Atopic Dermatitis and ASLAN004 • Company introduction and ASLAN004 Dr Carl Firth • A closer look: Key factors affec...
21.01.2022ASLAN Pharmaceuticals : Company Presentation January 2022Company presentation January 2022 NASDAQ: ASLN 1 Legal disclaimer This presentation contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of ASLAN Pharmaceuticals Limited (...
10.01.2022ASLAN Pharmaceuticals : Company Presentation January 2022Company presentation January 2022 NASDAQ: ASLN 1 Legal disclaimer This presentation contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of ASLAN Pharmaceuticals Limited (...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In